The Discounted Cash Flow (DCF) valuation of Ultragenyx Pharmaceutical Inc (RARE) is (313.16) USD. With the latest stock price at 28.71 USD, the upside of Ultragenyx Pharmaceutical Inc based on DCF is -1190.8%.
Based on the latest price of 28.71 USD and our DCF valuation, Ultragenyx Pharmaceutical Inc (RARE) is a sell. selling RARE stocks now will result in a potential gain of 1190.8%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 6.5% - 8.4% | 7.4% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (698.98) - (205.76) | (313.16) |
| Upside | -2534.6% - -816.7% | -1190.8% |